Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) stated cash, cash equivalents and marketable securities value of $64.7M
On Thursday Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) listed below -1.9% and ended at $7.76. The stock exchange capitalization came to $226.67 M and total traded volume was 35.6 K shares. During last trade, its maximum trading price was registered $8.01 and its the minimum trading price was kept in mind $7.72.
Research and research study expenses totaled Expenditures8.9 M for the third quarter of 2018, contrast with $6.2 M for the third quarter of 2017. General and administrative expenditures totaled $3.3 M for the 3rd quarter of 2018, contrast with $3.0 M in the 3rd quarter of 2017. Net loss totaled $11.9 M and $7.9 M for the third quarter of 2018 and 2017, respectively, with non-cash stock compensation expenditure of $1.1 M and $0.7 M for the 3rd quarter of 2018 and 2017, respectively.
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE), recently stated monetary results for the 3rd quarter ended September 30, 2018.
As of September 30, 2018, Aeglea had accessible money, cash equivalents and valuable securities of $64.7 M, which omits about $17.0 M in gross proceeds from shares of regular stock sold in a single transaction to new and existing investors in October 2018. Based on Aegleas current operating plan, and taking into consideration the $17.0 M raised in October 2018, management thinks it has enough capital resources to money expected operations to the middle of 2020.
As of September 30, 2018, Aeglea had a remaining grant receivable amounting to $2.4 M.
General and administrative expenses totaled $3.3 M for the 3rd quarter of 2018, contrast with $3.0 M in the 3rd quarter of 2017. This increase was primarily Because of additional worker payment expenses connected to the structure out of Aegleas management team to support business development. Net loss totaled $11.9 M and $7.9 M for the third quarter of 2018 and 2017, respectively, with non-cash stock payment expense of $1.1 M and $0.7 M for the 3rd quarter of 2018 and 2017, respectively.
The grant contract concluded in May 2018 with the full $19.8 M grant acknowledged as income over the life of the award. Aeglea did not acknowledge any grant incomes in the third quarter of 2018, contrast with $1.3 M in the third quarter of 2017. As of September 30, 2018, Aeglea had a staying grant receivable totaling $2.4 M.
In the liquidity ratio analysis; Aeglea BioTherapeutics, Inc.s (AGLE) current ratio was 6.00. The company has the institutional ownership of 80.50% while the Beta element was 1.05. The stocks RSI amounts to 48.37.
Research and development expenses totaled Expenditures8.9 M for the third quarter of 2018, contrast with $6.2 M for the third quarter 3rd 2017.
